Transplantation for CML

2010

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

Original languageEnglish (US)
Pages (from-to)1860-1861
Number of pages2
JournalBlood
Volume115
Issue number10
DOIs
StatePublished - Mar 11 2010

Fingerprint

Emitter coupled logic circuits
Stem Cell Transplantation
Stem cells
Blood
Transplantation
Safety
Therapeutics
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Transplantation for CML : 2010. / Maziarz, Richard.

In: Blood, Vol. 115, No. 10, 11.03.2010, p. 1860-1861.

Research output: Contribution to journalArticle

Maziarz, Richard. / Transplantation for CML : 2010. In: Blood. 2010 ; Vol. 115, No. 10. pp. 1860-1861.
@article{812be396481c46d89cde78b420682296,
title = "Transplantation for CML: 2010",
abstract = "In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.",
author = "Richard Maziarz",
year = "2010",
month = "3",
day = "11",
doi = "10.1182/blood-2009-12-255844",
language = "English (US)",
volume = "115",
pages = "1860--1861",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Transplantation for CML

T2 - 2010

AU - Maziarz, Richard

PY - 2010/3/11

Y1 - 2010/3/11

N2 - In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

AB - In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

UR - http://www.scopus.com/inward/record.url?scp=77950442553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950442553&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-12-255844

DO - 10.1182/blood-2009-12-255844

M3 - Article

VL - 115

SP - 1860

EP - 1861

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -